Table 5. Univariate and Multivariate Cox Proportional Hazards Regression Analysis of Overall Survival for 280 Matched Patients.
| Characteristic | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Female sex | 1.19 (0.67-2.13) | .50 | NA | NA |
| BMI | 1.01 (0.96-1.07) | .70 | NA | NA |
| First-line chemotherapy regimen | ||||
| FOLFIRINOX | 1 [Reference] | |||
| GA | 1.50 (1.00-2.26) | .05 | 1.48 (0.97-2.26) | .07 |
| Baseline CA 19-9 level, U/mL | 1.01 (0.99-1.03) | .30 | NA | NA |
| Tumor site | ||||
| Head or neck | 1 [Reference] | |||
| Body or tail | 0.78 (0.39-1.56) | .50 | NA | NA |
| No. of chemotherapy cycles | 0.72 (0.52-1.01) | .06 | 0.73 (0.52-1.02) | .06 |
Abbreviations: BMI, body mass index; CA 19-9, cancer antigen 19-9; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; GA, gemcitabine plus nanoparticle albumin-bound paclitaxel; HR, hazard ratio; NA, not applicable.